Information
2010 NEWS RELEASES
STEMEDICA INTERNATIONAL ANNOUNCES JOINT VENTURE WITH ANC BIO GROUP
(Source: Oct 5 2010; Stemedica Cell Technologies, Inc.)
Stemedica International, S.A., (“Stemedica”), a wholly owned subsidiary of Stemedica Cell Technologies, Inc., announced the signing of an agreement to form a joint venture with AnC Bio, a global manufacturer of stem cell-based products. The new venture, StemedicaAnC, will manufacture stem cells developed by Stemedica for the treatment of ischemic stroke and other degenerative disorders. The initial manufacturing capacity of this alliance will produce enough products to meet the Company’s five-year revenue projections, with an expansion capacity to manufacture multiple stem cell products to meet the anticipated long-term growth of the international market for stem cells.
STEMEDICA ANNOUNCES COMPLETION OF CLINICAL STEM CELL MASTER BANK
(Source: September 14 2010; Stemedica Cell Technologies, Inc.)
Stemedica Cell Technologies, Inc., a world leader in adult stem cell manufacturing and research, announced today that it has completed its proprietary master bank of mesenchymal bone marrow-derived stem cells. The master cell bank was manufactured in accordance with FDA Good Manufacturing Practices (cGMP). The cell bank has successfully passed all the necessary safety testing required by the FDA and is in compliance with the U.S. Code of Federal Regulations. Stem cells from the master bank will be used to support clinical trials in the United States and worldwide. The master bank together with its parent bank has the capacity to treat up to 300,000 patients participating in approved clinical trials.
STEMEDICA ANNOUNCES THE APPOINTMENT OF DR. CÉSAR AMESCUA GARCIA AS MEDICAL AND REGULATORY
AFFAIRS DIRECTOR – LATIN AMERICA
(Source: June 24 2010; Stemedica Cell Technologies, Inc.)
Dr. AmesCua will be responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica’s stem cell products for use in clinical (human) trials which follow the criteria required by the FDA in the United States.
DR. MAYNARD HOWE, CEO OF STEMEDICA, THE LEADING ALLOGENEIC ADULT STEM CELL MANUFACTURER,
JOINS USO BOARD OF GOVERNORS
(Source: June 11 2010; Stemedica Cell Technologies, Inc.)
Dr. Maynard A. Howe, CEO and Vice Chairman of Stemedica Cell Technologies Inc. (“Stemedica”), an allogeneic adult stem cell manufacturer, was welcomed as the newest member of the USO Board of Governors during their May Board Meeting held in San Antonio, Texas.
STEMEDICA ANNOUNCES THE APPOINTMENT OF DR. LEV VERKH AS CHIEF REGULATORY AND CLINICAL
DEVELOPMENT OFFICER
(Source: June 1 2010; Stemedica Cell Technologies, Inc.)
Stemedica Cell Technologies, Inc., a leader in adult stem cell research and manufacturing, announced today the appointment of Lev Verkh, PhD as Chief Regulatory and Clinical Development Officer. Dr. Verkh will be responsible for managing all regulatory activities and clinical trials on behalf of the company.
FDA
APPROVES STEMEDICA IND APPLICATION FOR ISCHEMIC STROKE CLINICAL TRIAL
(Source: April 20, 2010; Stemedica Cell Technologies, Inc.)
Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that the U.S. Food and Drug Administration (FDA) approved its application for an Investigational New Drug (IND) for a clinical trial for ischemic stroke using Stemedica's high potency proprietary allogeneic stem cells (adult human).
STEMEDICA FILES IND APPLICATION WITH FDA FOR TREATMENT OF STROKE WITH ADULT ALLOGENEIC
MESENCHYMAL STEM CELLS
(Source: March 19, 2010; Stemedica Cell Technologies, Inc.)
Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it has filed an Investigative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial. The trial will assess the safety, tolerability and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.
PRESS RELEASES ONLINE
We also post our press releases and other news information to our blogs
Stemedica Blog (
Wordpress.com)
Stemedica News (
blogger.com)